The development of anti-inflammatory drugs that address placental oxidative stress and systemic state of low-grade inflammation-lowering CCL2, CXCL1, CXCL8, CXCL9 and CXCL10 might be of potential value in GDM treatment. This evidence concerns the gene CCL2 and gestational diabetes.